Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad.[2] It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing.[3] It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico.[1] In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.[4]
The company was founded by a Jain pharmacist Hasmukh Chudgar in 1977[5] and was incorporated in 1985.[6]
In 2013, ChrysCapital acquired 16.14% stake in the company, and in 2015, ChrysCapital subsequently sold 10.13% to Singapore-based Temasek Holdings[7] and in 2017, it further diluted 3.01% stake to Capital International. Though, by May 2020, ChrysCapital bought back Capital International's stake.[8] Currently, the Chudgar family, owns 83.85% stake in the company, with 10.13% being held by Temasek Holdings, and 6.02% by ChrysCapital.[6]
As of March 2021, the company is operating 19 manufacturing facilities globally - 13 in India, 5 in the UK, and 1 in Mexico.[6] The company has set up a new manufacturing facility in PHARMEZ (Bavla, near Ahmedabad) with capacity to manufacture and export more than 1 billion solid dosages and 5 million injectables.[9]
Divisions
Biologics Unit (formerly, Intas Biopharmaceuticals)
In 2006, an independent biotechnology division of Intas Pharmaceuticals was incorporated as Intas Biopharmaceuticals by Urmish Chudgar, a hematologist. Later in 2012-13, the subsidiary was merged with the parent company Intas Pharmaceuticals Limited.[10] This division is involved in development and manufacturing of biosimilar products based on recombinant DNA and monoclonal antibodies.[11]
The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilarFilgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.[12] In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as neutropenia.[13][14]
Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.[15]
Subsidiaries
Accord Healthcare
London-headquartered Accord Healthcare is a fully-owned subsidiary of Intas Pharmaceuticals, which deals with large-scale generic pharmaceuticals across Europe and North America markets. It also manages an American R&D unit which is located at Research Triangle Park, Durham. As of 2018, the company has approval for 89 Abbreviated New Drug Applications and is selling 255 dosing presentations.[16]
In 2018, Intas' subsidiary Accord Healthcare reopened Sanofi 's Fawdon plant in the UK for manufacturing generic effervescent medicines. The plant was acquired in 2015 after Sanofi closed the facility.[21] This is the fifth manufacturing location for Accord in the country after Harrow, Barnstaple, Haverhill, and Didcot.[22]
In December 2022, upon compliance inspection by the FDA, the plant was found to be in violation of most established laboratory practices and protocols, as revealed in the stunning report from January 2023.[24]
Testing conducted on behalf of the American military by the laboratory Valisure revealed that generic tacrolimus manufactured by Intas was not a functional substitute for the brand name drug.[25]
₹22,379 crore (US$2.8 billion) (FY23)[1]
₹2,422 crore (US$300 million) (FY23)[1]
